Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recent developments in the legal battle over the planned $3.3 billion UnitedHealth Group (NYSE: UHG) acquisition of Amedisys (Nasdaq: AMED) have moved the ...

UnitedHealth Group said in a court filing it is working with Amedisys to identify potential buyers for at least 128 home ...

Two whistleblowers have adequately alleged that Amedisys Inc. violated the False Claims Act by improperly billing Medicare and other federal health-care programs for home health services, a New York ...

Amedisys has a 1-year low of $82.15 and a 1-year high of $98.95. The company has a market cap of $3.03 billion, a PE ratio of 36.71, a price-to-earnings-growth ratio of 1.82 and a beta of 0.73.

UnitedHealth Group says the Justice Department’s antitrust challenge to its proposed $3.3 billion purchase of Amedisys is wrong on the merits and threatens to deprive consumers of benefits from ...

UnitedHealth Group says the Justice Department’s antitrust challenge to its proposed $3.3 billion purchase of Amedisys is wrong ... hospice and home care business, the two companies argue ...